Citius Oncology, Inc. Proceeds from Notes Payable
Citius Oncology, Inc. (CTOR) reported Proceeds from Notes Payable of $9.63 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-14
- Citius Oncology, Inc. proceeds from notes payable for the quarter ending 2025-06-30 was $0.00.
- Citius Oncology, Inc. proceeds from notes payable for fiscal 2024 was $3.80M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.63M 10-Q · filed 2026-08-14 | |||
| 2025-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $3.80M 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | $3.80M 10-Q · filed 2025-05-14 | |||
| 2024-09-30 | $3.80M 10-K · filed 2025-12-23 | |||
| 2024-06-30 | $400.00K 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |